Dr. Christopher Buck | Expanding Our Knowledge of Viral Evolution

Dr. Christopher Buck | Expanding Our Knowledge of Viral Evolution

Vitamin D has been studied as a treatment for a large number of diseases and conditions, from cancer to autism to COVID-19. However, its mode of action is not completely understood. Professor Ralf Herwig carries out his research at HG Pharma GmbH (Austria) and Ulster University (UK). His vital work explores the role of vitamin D in the body with a view to unlocking its potential as a treatment for a variety of health conditions involving the immune system.

Dr. Rebecca Rose | Adjusting Ventilator Settings Could Improve Outcomes for Premature Infants

Dr. Rebecca Rose | Adjusting Ventilator Settings Could Improve Outcomes for Premature Infants

Premature birth puts infants at a greater risk of developing various medical conditions, including a chronic lung disease known as bronchopulmonary dysplasia – or BPD for short. Dr. Rebecca Rose, a neonatologist at Indiana University, recently explored how modulating ventilator settings used for very premature newborns can significantly improve their outcomes.

Prof. Alastair Florence | Optimising Pharmaceutical Production Using Digital Models

Prof. Alastair Florence | Optimising Pharmaceutical Production Using Digital Models

The development of safe and effective medicines that meet strict regulatory requirements has traditionally involved extensive experimentation, which can be laborious and costly. Incorporating digital processes, which can be used to produce individual pharmaceutical components, may provide a solution to manufacturing challenges by reducing development time, resource requirements, and costs. The Future Continuous Manufacturing and Advanced Crystallisation Hub, a flagship project at CMAC, at the University of Strathclyde, along with collaborators throughout the UK, has investigated the feasibility of using digital models to reduce costs, time and waste for high quality pharmaceutical production.

Prof. Christian Bréchot | ALF5755: A New Therapeutic Avenue for Alzheimer’s and Diabetic Neuropathy

Prof. Christian Bréchot | ALF5755: A New Therapeutic Avenue for Alzheimer’s and Diabetic Neuropathy

Many diseases become more likely to emerge as we age, with metabolic disorders such as diabetes, and neurodegenerative conditions, such as Alzheimer’s disease, representing two frequent manifestations of poor health in old age. While many age-related diseases present very differently, many share common underlying mechanisms. These include inflammation, a build-up of reactive oxygen molecules that can damage cellular components, and a lack of sensitivity to insulin. Treatments that can effectively target these mechanisms could have transformational effects on the age-related diseases that are fueled by them, including potentially preventing such diseases from developing in the first place. Prof. Christian Bréchot and colleagues at The Healthy Aging Company have developed a drug candidate: ALF5755, the pharmacological name of a protein called Hepatocarcinoma-Intestine-Pancreas, or HIP for short, also named Reg3A, that has shown exciting evidence of effectiveness on the cognitive disorders which occur during Alzheimer’s disease and the peripheral nerve damage that often occurs in diabetes, which is called diabetic neuropathy.

Dr Christopher Buck | Mint: A Fresh Perspective in the Fight Against Covid

Dr Christopher Buck | Mint: A Fresh Perspective in the Fight Against Covid

Dr. Christopher Buck, a virologist at the US National Cancer Institute in Bethesda, Maryland, has been working to spread the word about a growing body of scientific literature suggesting that mint and related herbs can help fight Covid infections. In his recent review article, “The Mint Versus Covid Hypothesis,” he makes a case for the idea that decentralized clinical trials could be used to more thoroughly explore this exciting idea.

Dr Katty Kang | Deciphering the Molecular Origins of Brain Disorders

Dr Katty Kang | Deciphering the Molecular Origins of Brain Disorders

During brain development, anomalies may arise which lead to serious conditions such as epilepsy, triggering seizures and requiring lifelong monitoring and medication. However, the underlying causes and the way in which these defects occur are not completely understood. Dr Katty (Jing-Qiong) Kang and colleagues at Vanderbilt University Medical Centre in the USA have conducted extensive research into the molecular mechanisms associated with developmental brain disorders, with a focus on genetic epilepsy. They propose novel therapeutic targets to effectively manage symptoms and improve clinical outcomes by targeting the root cause.